Senti Biosciences, Inc. (SNTI), Tuesday announced new data from its ongoing trial of SENTI-202, evaluating the safety, efficacy, and pharmacodynamics of the treatment, when administered after Fludarabine/lymphodepletion in patients with relapsed or refractory Acute Myeloid Leukemia.
The findings revealed that 50 percent of patients at the Recommended Phase 2 Dose or RP2D, and 50 percent of all trial patients achieved an Overall Response Rateoutcome.
Meanwhile, 42 percent of patients at the RP2D and 39 percent of all patients overall achieved a Complete Remission or Complete Remission with Partial Hematologic Recovery.
Notably, SENTI-202 was detected in the peripheral blood of all patients, with pharmacokinetics that were consistent with other allogeneic NK cell therapies.
Currently, SNTI is trading at $2.58, up 8.27 percent on the Nasdaq.
For comments and feedback contact: editorial@rttnews.com
Economic News
What parts of the world are seeing the best (and worst) economic performances lately? Click here to check out our Econ Scorecard and find out! See up-to-the-moment rankings for the best and worst performers in GDP, unemployment rate, inflation and much more.
September 04, 2026 15:08 ET The job report and foreign trade data were the main economic news from the U.S. in the first week of September. Elsewhere in North America, the Canadian central bank announced its latest policy decision. Inflation data from Eurozone was the highlight in Europe. The latest interest rate decision by the Reserve Bank of New Zealand drew attention in Asia.